ENTITY
Guangzhou Baiyunshan Pharmaceutical

Guangzhou Baiyunshan Pharmaceutical (874 HK)

125
Analysis
Health Care • China
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited is a major Chinese pharmaceutical firm engaged in the research, development, manufacturing, and sales of traditional Chinese medicines, Western pharmaceuticals, chemical raw materials, and health products. The company operates across segments including Great Southern Traditional Chinese Medicine, Great Health, Great Commerce, and Great Medical. It was founded on September 1, 1997, and is headquartered in Guangzhou, China.
more
bullish•Great Wall Motor
•23 Jun 2025 17:58

A/H Premium Tracker (To 20 June 2025):Ā  Skew Move Continues as SB Buys But AH Premia Rise

AH Premia bounced this past week to 20 June. Possible "sell the news" on the HK headline of RMB counters coming to Southbound. But "beautiful skew"...

Logo
512 Views
Share
•14 Jun 2025 21:30

A/H Premium Tracker (To 13 June 2025):Ā  HUGE H-Share Outperf Across The Board, "Beautiful Skew Move"

H-shares outperform A-shares dramatically with "beautiful skew" as very wide AH premia shrink most, medium less, smallest premia the least. Feels...

Logo
730 Views
Share
•02 Jun 2025 10:30

Hong Kong Connect Flows (May): Inflows Slowed Down

We analyzed the Hong Kong Connect Scheme for May and highlighted flows for Tencent, Meituan, Xiaomi, CCB, China Mobile. Inflows in May is slowed...

Logo
712 Views
Share
bullish•Flat Glass
•31 May 2025 17:06

A/H Premium Tracker (To 30 May 2025):Ā  Narrow Premia Hs Worst Performers, BYD Relents

AH Premia contracted but it was mostly in the 40-100% area where they did. Tighter than 40% (or H premium) saw Hs underperform. Quiddity alpha...

Logo
786 Views
Share
•02 May 2025 10:00

Hong Kong Connect Flows (April): US$22bn Inflows

We analyzed the Hong Kong Connect Scheme for April and highlighted flows for Alibaba, TraHK HSI ETF, Tencent, Meituan, HSCEI ETF.

Logo
339 Views
Share
x